fashion -WSS

fashion

author：fashion 2025-09-27 19:37:53 - browse：72986

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Prescription digital therapeutics are key to pharma’s future

WSS

Crowdfunding for unproven stem cell procedures spreads misinformation

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Hubble vs. James Webb telescope images: See the difference

Crowdfunding for unproven stem cell procedures spreads misinformation

Hubble vs. James Webb telescope images: See the difference

Flagship Pioneering startup Sonata Therapeutics lays off 21

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare proposal to cover medical devices draws a mixed reaction

Researchers tackle phage therapy hurdles for wider adoption

Walensky prepares to leave CDC — and Congress — behind

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Moonlake's readout produced a cash windfall. Risks remain

Reporting on presidential health from Reagan to Trump and Biden

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Secretariat’s lessons for human medicine

After affirmative action ruling, medical educators look to 'holistic review'

Vertex cell therapy lets patients with type 1 diabetes stop insulin

focus

AstraZeneca lung cancer study comes in below expectations

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Hubble vs. James Webb telescope images: See the difference

Abridge raises $150m as clinical notes automation market heats up

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Drug cartel violence flares in western Mexico after vigilante leader's killing

leisure time

focus

knowledge

Wikipedia